간세포암 : 세계 시장 전망, 역학, 경쟁 구도, 시장 예측 보고서(주요 32개 시장)(2025-2035년)

Global Hepatocellular Carcinoma Market Outlook

Thelansis's "Global Hepatocellular Carcinoma Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (Top 32 Markets) - 2025 To 2035" covers disease overview, epidemiology, kidney biopsy cases, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Hepatocellular Carcinoma treatment modalities options for the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America).

Hepatocellular Carcinoma (HCC) Overview

Hepatocellular carcinoma (HCC) is the most common primary liver malignancy, arising predominantly in the context of chronic liver disease and cirrhosis, with hepatitis B and C viral infections, alcohol-related liver disease, metabolic dysfunction-associated steatotic liver disease, and aflatoxin exposure representing principal aetiological drivers of oncogenic hepatocyte transformation. Somatic alterations in TERT promoter, TP53, CTNNB1, and ARID1A alongside epigenetic dysregulation underpin tumourigenesis. Patients present with right upper quadrant pain, weight loss, jaundice, and decompensated liver disease, with many diagnosed incidentally through surveillance programmes. Serum alpha-fetoprotein alongside multiphasic contrast-enhanced CT or MRI demonstrating arterial enhancement with venous washout establishes diagnosis without biopsy in cirrhotic patients, per EASL and AASLD criteria. Barcelona Clinic Liver Cancer staging integrates tumour burden, liver function, and performance status to guide therapeutic allocation. Surgical resection or ablation offers curative intent in early-stage disease, with liver transplantation providing definitive treatment within Milan criteria. Transarterial chemoembolisation and radioembolisation address intermediate-stage disease. Systemic therapy has been transformed by immunotherapy combinations; atezolizumab plus bevacizumab and durvalumab plus tremelimumab are established first-line standards for advanced HCC, with lenvatinib and sorafenib as alternatives. Cabozantinib, ramucirumab, and regorafenib address second-line disease. Prognosis varies markedly with stage and hepatic reserve; multidisciplinary management, surveillance optimisation, and patient-centred supportive care are integral to long-term outcomes.

Key Highlights

• In France, incident cases are projected to increase from 7,874 in 2025 to 8,033 by 2035, indicating marginal growth in disease burden.
• Diagnosis rate remains high at 85.0%, reflecting strong detection capabilities across healthcare systems.
• Treatment rate stands at 76.2%, highlighting a residual gap between diagnosed and treated patients.
• The treatment paradigm has shifted toward immunotherapy-based combinations (IO + anti-VEGF/CTLA-4) as the new standard of care.
• Persistent unmet need exists in post-progression settings and treatment-resistant populations, despite recent therapeutic advances.

Market Overview

• The United Kingdom uHCC market is projected to grow from $49M in 2025 to $71M by 2035, reflecting steady market expansion.
• Market growth is driven by:
• Increasing adoption of high-cost immunotherapy combinations
• Expansion of eligible patient population due to improved diagnosis
• Despite modest epidemiological growth, market value is supported by premium-priced biologics and longer treatment duration.
• Strong reimbursement frameworks in Europe continue to facilitate access to innovative therapies.
• Future growth will depend on next-generation immunotherapies and novel combination strategies targeting resistance mechanisms.

Market Definition:

• North America (United States, Canada)
• Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
• Middle East (Saudi Arabia, UAE, Kuwait, Turkey)
• Asia Pacific (Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam)
• Africa (Egypt, Nigeria, South Africa, Morocco)
• South / Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• North America (United States, Canada)
• Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
• Middle East (Saudi Arabia, UAE, Kuwait, Turkey)
• Asia Pacific (Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam)
• Africa (Egypt, Nigeria, South Africa, Morocco)
• South / Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru)

Companies Mentioned

• InnoBM Pharmaceuticals Co., Ltd.
• Chengdu New Radiomedicine Technology Co. LTD.
• BeiGene
• Hoffmann-La Roche
• Beijing Gene Key Life Technology Co., Ltd
• Akeso
• AstraZeneca
• Tvardi Therapeutics, Incorporated
• Genentech, Inc.
• RayzeBio, Inc.
• Shanghai Henlius Biotech

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
• Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)